Pharsight

Drugs that contain Pirfenidone

1. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561217 GENENTECH INC Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
Jan, 2022

(2 years ago)

US7988994 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

US7767225 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

US8753679 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

US7767700 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US8420674 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US7696236 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US7696326 GENENTECH INC Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
Dec, 2027

(3 years from now)

US8383150 GENENTECH INC Granulate formulation of pirfenidone and pharmaceutically acceptable excipients
May, 2028

(3 years from now)

US8609701 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US8592462 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US7566729 GENENTECH INC Modifying pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US7635707 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US8754109 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

US7816383 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US8084475 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

US8013002 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US7910610 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US8318780 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US8648098 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

US8778947 GENENTECH INC Methods of administering pirfenidone therapy
Aug, 2033

(9 years from now)

US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
Mar, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-1...

Dosage: TABLET;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents